Literature DB >> 15826241

The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.

Rosa Salvioli1, Massimo Tatti, Susanna Scarpa, Sabrina Maria Moavero, Fiorella Ciaffoni, Federica Felicetti, Christine R Kaneski, Roscoe O Brady, Anna Maria Vaccaro.   

Abstract

The properties of the endolysosomal enzyme GCase (glucosylceramidase), carrying the most prevalent mutation observed in Gaucher patients, namely substitution of an asparagine residue with a serine at amino acid position 370 [N370S (Asn370-->Ser) GCase], were investigated in the present study. We previously demonstrated that Sap (saposin) C, the physiological GCase activator, promotes the association of GCase with anionic phospholipid-containing membranes, reconstituting in this way the enzyme activity. In the present study, we show that, in the presence of Sap C and membranes containing high levels of anionic phospholipids, both normal and N370S GCases are able to associate with the lipid surface and to express their activity. Conversely, when the amount of anionic phospholipids in the membrane is reduced (approximately 20% of total lipids), Sap C is still able to promote binding and activation of the normal enzyme, but not of N370S GCase. The altered interaction of the mutated enzyme with anionic phospholipid-containing membranes and Sap C was further demonstrated in Gaucher fibroblasts by confocal microscopy, which revealed poor co-localization of N370S GCase with Sap C and lysobisphosphatidic acid, the most abundant anionic phospholipid in endolysosomes. Moreover, we found that N370S Gaucher fibroblasts accumulate endolysosomal free cholesterol, a lipid that might further interfere with the interaction of the enzyme with Sap C and lysobisphosphatidic acid-containing membranes. In summary, our results show that the N370S mutation primarily affects the interaction of GCase with its physiological activators, namely Sap C and anionic phospholipid-containing membranes. We thus propose that the poor contact between N370S GCase and its activators may be responsible for the low activity of the mutant enzyme in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826241      PMCID: PMC1184565          DOI: 10.1042/BJ20050325

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Solubilization of glucocerebrosidase from human placenta and demonstration of a phospholipid requirement for its catalytic activity.

Authors:  G L Dale; D G Villacorte; E Beutler
Journal:  Biochem Biophys Res Commun       Date:  1976-08-23       Impact factor: 3.575

2.  A lipid associated with the antiphospholipid syndrome regulates endosome structure and function.

Authors:  T Kobayashi; E Stang; K S Fang; P de Moerloose; R G Parton; J Gruenberg
Journal:  Nature       Date:  1998-03-12       Impact factor: 49.962

3.  A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies.

Authors:  J M Aerts; W E Donker-Koopman; G J Murray; J A Barranger; J M Tager; A W Schram
Journal:  Anal Biochem       Date:  1986-05-01       Impact factor: 3.365

4.  Glucocerebrosidase: reconstitution from macromolecular components depends on acidic phospholipids.

Authors:  M W Ho; N D Light
Journal:  Biochem J       Date:  1973-11       Impact factor: 3.857

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro.

Authors:  M W Ho; J S O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

7.  Biosynthesis of the lysosomal enzyme glucocerebrosidase.

Authors:  A H Erickson; E I Ginns; J A Barranger
Journal:  J Biol Chem       Date:  1985-11-15       Impact factor: 5.157

8.  X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease.

Authors:  Hay Dvir; Michal Harel; Andrew A McCarthy; Lilly Toker; Israel Silman; Anthony H Futerman; Joel L Sussman
Journal:  EMBO Rep       Date:  2003-07       Impact factor: 8.807

9.  Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen.

Authors:  M T Vanier
Journal:  Biochim Biophys Acta       Date:  1983-01-07

10.  Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C.

Authors:  Rosa Salvioli; Susanna Scarpa; Fiorella Ciaffoni; Massimo Tatti; Carlo Ramoni; Marie T Vanier; Anna Maria Vaccaro
Journal:  J Biol Chem       Date:  2004-02-02       Impact factor: 5.157

View more
  19 in total

1.  Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.

Authors:  Marc N Offman; Marcin Krol; Israel Silman; Joel L Sussman; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

2.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

Authors:  Zhanqian Yu; Anu R Sawkar; Lisa J Whalen; Chi-Huey Wong; Jeffery W Kelly
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

3.  Molecular imaging of membrane interfaces reveals mode of beta-glucosidase activation by saposin C.

Authors:  Jean-René Alattia; James E Shaw; Christopher M Yip; Gilbert G Privé
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

Review 4.  GBA-Associated Parkinson's Disease and Other Synucleinopathies.

Authors:  Ziv Gan-Or; Christopher Liong; Roy N Alcalay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-08       Impact factor: 5.081

5.  Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Authors:  Raquel Romero; Arvind Ramanathan; Tony Yuen; Debsindhu Bhowmik; Mehr Mathew; Lubna Bashir Munshi; Seher Javaid; Madison Bloch; Daria Lizneva; Alina Rahimova; Ayesha Khan; Charit Taneja; Se-Min Kim; Li Sun; Maria I New; Shozeb Haider; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

Review 6.  Exploring genetic modifiers of Gaucher disease: The next horizon.

Authors:  Brad A Davidson; Shahzeb Hassan; Eric Joshua Garcia; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2018-09-11       Impact factor: 4.878

7.  X-ray and biochemical analysis of N370S mutant human acid β-glucosidase.

Authors:  Ronnie R Wei; Heather Hughes; Susan Boucher; Julie J Bird; Nicholas Guziewicz; Scott M Van Patten; Huawei Qiu; Clark Qun Pan; Tim Edmunds
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

Review 8.  The role of saposin C in Gaucher disease.

Authors:  Rafael J Tamargo; Arash Velayati; Ehud Goldin; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2012-05-05       Impact factor: 4.797

9.  Lipid composition of microdomains is altered in a cell model of Gaucher disease.

Authors:  Leanne K Hein; Stephen Duplock; John J Hopwood; Maria Fuller
Journal:  J Lipid Res       Date:  2008-04-21       Impact factor: 5.922

10.  Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase.

Authors:  Melissa R Landon; Raquel L Lieberman; Quyen Q Hoang; Shulin Ju; Jose M M Caaveiro; Susan D Orwig; Dima Kozakov; Ryan Brenke; Gwo-Yu Chuang; Dmitry Beglov; Sandor Vajda; Gregory A Petsko; Dagmar Ringe
Journal:  J Comput Aided Mol Des       Date:  2009-06-12       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.